Stockhead’s Sarah Hughan sits down with Orthocell (ASX:OCC) chairman John Van Der Wielen to get the short end of the long story on the company’s latest news.

The regenerative medicine company has appointed two US-based executives to drive the market launch and sales of its nerve repair product, Remplir.

Remplir has proved a success in the Australian and New Zealand markets, and is just waiting on US government approval expected in the first quarter of 2025.

Tune in to hear Orthocell’s John Van Der Wielen on the new recruits, the world-leading product, and more.

 

This video was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreAusbiotechBiotechHealth

Featured Companies

You might be interested in